Literature DB >> 25088061

Preferences of older people for early diagnosis and disclosure of Alzheimer's disease (AD) before and after considering potential risks and benefits.

Stephanie M Robinson1, Michelle Canavan1, Shaun T O'Keeffe2.   

Abstract

Studies suggest that most people support screening for and disclosure of dementia, but it is not clear whether respondents have reflected on the benefits and risks of diagnosis. In this study, preferences, rated on a 7-point Likert scale, for diagnosis, disclosure and screening for AD were measured before and after discussion of the potential benefits and hazards of diagnosis in 132 hospital and community subjects in Galway, Ireland. At baseline the percentages with a positive attitude (Likert rating of 5-7) were 79.6% for diagnosis, 85.7% for disclosure and 59.3% for screening. On follow-up, there was no significant change in disclosure responses (12 more positive, 18 more negative, 102 unchanged (p=0.2), 78.1% positive attitude) while there were significant declines in ratings for diagnosis (11 more positive, 27 more negative, 94 unchanged (p=0.03), 69.1% with positive attitude) and screening (10 more positive, 35 more negative, 87 unchanged (p<0.0001), 42.1% positive attitude). In conclusion, although most people want to 'know' if they have AD, there is a diminishing degree of support from disclosure to diagnostic assessment to screening. Preferences for diagnosis and screening decline when respondents have the opportunity to consider the consequences of their decision.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Disclosure of dementia; Patient preferences; Screening acceptance; Stigma

Mesh:

Year:  2014        PMID: 25088061     DOI: 10.1016/j.archger.2014.07.010

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  9 in total

1.  Concern about developing Alzheimer's disease or dementia and intention to be screened: An analysis of national survey data.

Authors:  Weizhou Tang; Kristie Kannaley; Daniela B Friedman; Valerie J Edwards; Sara Wilcox; Sue E Levkoff; Rebecca H Hunter; Cheryl Irmiter; Basia Belza
Journal:  Arch Gerontol Geriatr       Date:  2017-03-01       Impact factor: 3.250

2.  Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing.

Authors:  Melissa J Armstrong; Gary S Gronseth; Gregory S Day; Carol Rheaume; Slande Alliance; C D Mullins
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Jul-Sep       Impact factor: 2.703

Review 3.  Caregiver Burden in Different Stages of Alzheimer's Disease.

Authors:  Elif Koca; Özlem Taşkapilioğlu; Mustafa Bakar
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

Review 4.  Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Authors:  Harald Hampel; Sid E O'Bryant; José L Molinuevo; Henrik Zetterberg; Colin L Masters; Simone Lista; Steven J Kiddle; Richard Batrla; Kaj Blennow
Journal:  Nat Rev Neurol       Date:  2018-11       Impact factor: 42.937

5.  Detecting dementia among older, ethnically diverse residents of rural subsidized housing.

Authors:  Lisa Kirk Wiese; Christine L Williams; Debra Hain; David Newman; Christina P Houston; Carolina Kaack; James E Galvin
Journal:  Geriatr Nurs       Date:  2020-10-08       Impact factor: 2.361

6.  Clinical and research value of the new diagnostic criteria for Alzheimer's disease.

Authors:  Chen Wei
Journal:  Shanghai Arch Psychiatry       Date:  2015-04-25

7.  'Because my brain isn't as active as it should be, my eyes don't always see': a qualitative exploration of the stress process for those living with posterior cortical atrophy.

Authors:  Emma Harding; Mary Pat Sullivan; Rachel Woodbridge; Keir X X Yong; Anne McIntyre; Mary L Gilhooly; Kenneth J Gilhooly; Sebastian J Crutch
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

Review 8.  Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program.

Authors:  Stina Saunders; Graciela Muniz-Terrera; Julie Watson; Charlotte L Clarke; Saturnino Luz; Alison R Evans; Craig W Ritchie
Journal:  Alzheimers Dement (N Y)       Date:  2018-12-12

9.  Alzheimer's Disease - Why We Need Early Diagnosis.

Authors:  Jill Rasmussen; Haya Langerman
Journal:  Degener Neurol Neuromuscul Dis       Date:  2019-12-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.